Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors
Jin-Jun Liu, Brian Higgins, Grace Ju, et al.
Biomedical Optics Express
|
July 5, 2021
Automated image processing pipeline for adaptive optics scanning light ophthalmoscopy
Alexander E Salmon, Robert F Cooper, Min Chen, et al.
Cancer Research
|
December 20, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
Hong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 31, 2006
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Christian Tovar, James Rosinski, Zoran Filipovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
David B Solit, Fuzhong F Zheng, Maria Drobnjak, et al.
Cancer Chemotherapy and Pharmacology
|
May 10, 2011
Preclinical evaluation of the novel multi-targeted agent R1530
Kenneth Kolinsky, Christian Tovar, Yu-E Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2014
Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach
Brian Higgins, Kelli Glenn, Antje Walz, et al.
Cancer Research
|
June 17, 2010
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
Hong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Cancer Cell
|
September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
David B Agus, Robert W Akita, William D Fox, et al.
Cancer Research
|
February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy
Sherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors
Jin-Jun Liu, Brian Higgins, Grace Ju, et al.
Biomedical Optics Express
|
July 5, 2021
Automated image processing pipeline for adaptive optics scanning light ophthalmoscopy
Alexander E Salmon, Robert F Cooper, Min Chen, et al.
Cancer Research
|
December 20, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
Hong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 31, 2006
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Christian Tovar, James Rosinski, Zoran Filipovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
David B Solit, Fuzhong F Zheng, Maria Drobnjak, et al.
Cancer Chemotherapy and Pharmacology
|
May 10, 2011
Preclinical evaluation of the novel multi-targeted agent R1530
Kenneth Kolinsky, Christian Tovar, Yu-E Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2014
Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach
Brian Higgins, Kelli Glenn, Antje Walz, et al.
Cancer Research
|
June 17, 2010
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
Hong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Cancer Cell
|
September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
David B Agus, Robert W Akita, William D Fox, et al.
Cancer Research
|
February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy
Sherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Page
of 6